Table 1.
Cytotoxicity and anti-HSV-1 activity of CHLA, CHLI, PUG, and PUN in A549 cellsa
| Compound | Mean CC50b (μM) ± SEM | Anti-HSV-1 effect |
|
|---|---|---|---|
| Mean EC50c (μM) ± SEM | SId | ||
| CHLA | 316.87 ± 9.01 | 17.02 ± 2.82 | 18.62 |
| CHLI | 330.83 ± 9.07 | 20.85 ± 2.40 | 15.87 |
| PUG | 318.84 ± 4.98 | 10.25 ± 1.13 | 31.11 |
| PUN | 310.85 ± 1.99 | 21.33 ± 1.77 | 14.57 |
| ACV | >2,000 | 14.45 ± 1.71 | >138.41 |
| FOS | >2,000 | 183.37 ± 25.18 | >10.91 |
a
The values shown are means from three independent experiments with each treatment performed in triplicate.
b
Cytotoxic effects were evaluated by XTT assay to determine the concentration of 50% cellular cytotoxicity (CC50) of the tested compounds.
c
Antiviral effects were evaluated by plaque assay to determine the effective concentration that achieved 50% inhibition (EC50) against HSV-1 infection.
d
SS, selectivity index. SI = CC50/EC50.